CN103524620A - 成纤维细胞生长因子受体-3(fgfr-3)抑制物和治疗的方法 - Google Patents

成纤维细胞生长因子受体-3(fgfr-3)抑制物和治疗的方法 Download PDF

Info

Publication number
CN103524620A
CN103524620A CN201310384769.3A CN201310384769A CN103524620A CN 103524620 A CN103524620 A CN 103524620A CN 201310384769 A CN201310384769 A CN 201310384769A CN 103524620 A CN103524620 A CN 103524620A
Authority
CN
China
Prior art keywords
antibody
fgfr
cell
people
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201310384769.3A
Other languages
English (en)
Chinese (zh)
Inventor
H·孙
L·刘
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ImClone LLC
Original Assignee
ImClone LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ImClone LLC filed Critical ImClone LLC
Publication of CN103524620A publication Critical patent/CN103524620A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201310384769.3A 2008-10-20 2009-10-15 成纤维细胞生长因子受体-3(fgfr-3)抑制物和治疗的方法 Pending CN103524620A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19685508P 2008-10-20 2008-10-20
US61/196,855 2008-10-20

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN200980141656.2A Division CN102186884B (zh) 2008-10-20 2009-10-15 成纤维细胞生长因子受体-3（fgfr-3）抑制物

Publications (1)

Publication Number Publication Date
CN103524620A true CN103524620A (zh) 2014-01-22

Family

ID=42062445

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201310384769.3A Pending CN103524620A (zh) 2008-10-20 2009-10-15 成纤维细胞生长因子受体-3(fgfr-3)抑制物和治疗的方法
CN200980141656.2A Expired - Fee Related CN102186884B (zh) 2008-10-20 2009-10-15 成纤维细胞生长因子受体-3（fgfr-3）抑制物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN200980141656.2A Expired - Fee Related CN102186884B (zh) 2008-10-20 2009-10-15 成纤维细胞生长因子受体-3（fgfr-3）抑制物

Country Status (17)

Country Link
US (3) US8043618B2 (enExample)
EP (1) EP2342232A2 (enExample)
JP (1) JP5577345B2 (enExample)
KR (1) KR101370798B1 (enExample)
CN (2) CN103524620A (enExample)
AR (1) AR073770A1 (enExample)
AU (1) AU2009307841B2 (enExample)
BR (1) BRPI0919832A8 (enExample)
CA (1) CA2741127C (enExample)
EA (1) EA021584B1 (enExample)
IL (1) IL211807A0 (enExample)
MX (1) MX2011004317A (enExample)
NZ (1) NZ592369A (enExample)
TW (1) TWI381848B (enExample)
UA (1) UA101681C2 (enExample)
WO (1) WO2010048026A2 (enExample)
ZA (1) ZA201101938B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114015770A (zh) * 2021-12-30 2022-02-08 佛山市第三人民医院(佛山市精神卫生中心) 精神分裂全外周血rna标志物fgfr3及其应用

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI381848B (zh) * 2008-10-20 2013-01-11 Imclone Llc 抗纖維母細胞生長因子受體-3 (fgfr-3) 抗體及包含其之醫藥組合物
EP3702371B1 (en) 2009-03-25 2022-11-02 Genentech, Inc. Anti-fgfr3 antibodies and methods using same
WO2013088191A1 (en) 2011-12-12 2013-06-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3
EA201591324A1 (ru) 2013-01-16 2016-01-29 Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль) Полипептид растворимого рецептора 3 фактора роста фибробластов (fgr3) для применения с целью предотвращения или лечения нарушений, связанных с замедлением роста скелета
RU2015137610A (ru) 2013-03-06 2017-04-10 Дженентек, Инк. Способы лечения и профилактики лекарственной резистентности злокачественных опухолей
TWI541022B (zh) * 2013-12-18 2016-07-11 應克隆公司 針對纖維母細胞生長因子受體－３（ｆｇｆｒ３）之化合物及治療方法
US10519240B2 (en) 2014-03-25 2019-12-31 Regeneron Pharmaceuticals, Inc. Anti-FGFR1c antibody-FGF21 fusion proteins
EP3151857A4 (en) * 2014-06-03 2018-04-18 Merck Sharp & Dohme Corp. Anti-blys antibodies
CN107073121A (zh) 2014-06-13 2017-08-18 基因泰克公司 治疗及预防癌症药物抗性的方法
AU2015311749B2 (en) * 2014-09-05 2018-06-21 Hyperfine Operations, Inc. Ferromagnetic augmentation for magnetic resonance imaging
UA122564C2 (uk) 2014-09-26 2020-12-10 Янссен Фармацевтика Нв Використання панелі мутантних генів fgfr для ідентифікації пацієнтів із раковим захворюванням, які піддаються лікуванню інгібітором fgfr
MX2017010595A (es) * 2015-02-19 2018-11-12 Bioclin Therapeutics Inc Métodos, composiciones, y equipos para tratamiento de cáncer.
US20180237424A1 (en) 2015-03-03 2018-08-23 Inserm (Institut National De La Sante Et De La Recherche Medicale) Fgfr3 antagonists
TW201711702A (zh) * 2015-06-04 2017-04-01 應克隆公司 使用針對纖維母細胞生長因子受體３（ｆｇｆｒ３）之化合物的療法
MA43416A (fr) 2015-12-11 2018-10-17 Regeneron Pharma Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3
RU2751483C2 (ru) 2016-07-07 2021-07-14 Пфайзер Инк. Полипептиды, являющиеся растворимыми рецепторами 3 фактора роста фибробластов (sfgfr3), и пути их применения
US20180244785A1 (en) * 2017-01-09 2018-08-30 Merrimack Pharmaceuticals, Inc. Anti-fgfr antibodies and methods of use
AU2021327387A1 (en) 2020-08-21 2023-05-04 Genzyme Corporation Fgfr3 antibodies and methods of use
WO2024107765A2 (en) * 2022-11-14 2024-05-23 Regeneron Pharmaceuticals, Inc. Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
WO2024152014A1 (en) 2023-01-13 2024-07-18 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof
WO2025240335A1 (en) 2024-05-13 2025-11-20 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
CA2450793A1 (en) 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
EP1697420A2 (en) * 2003-12-19 2006-09-06 Five Prime Therapeutics, Inc. Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
WO2007141278A2 (en) * 2006-06-06 2007-12-13 Crucell Holland B.V. Human binding molecules having killing activity against enterococci and staphylococcus aureus and uses thereof
CA2663388C (en) * 2006-09-07 2017-01-17 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
WO2009054873A2 (en) * 2007-08-02 2009-04-30 Novimmune S.A. Anti-rantes antibodies and methods of use thereof
TWI700293B (zh) * 2008-04-11 2020-08-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗體
US8187601B2 (en) * 2008-07-01 2012-05-29 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (FGFR3) binding proteins
TWI381848B (zh) * 2008-10-20 2013-01-11 Imclone Llc 抗纖維母細胞生長因子受體-3 (fgfr-3) 抗體及包含其之醫藥組合物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114015770A (zh) * 2021-12-30 2022-02-08 佛山市第三人民医院(佛山市精神卫生中心) 精神分裂全外周血rna标志物fgfr3及其应用

Also Published As

Publication number Publication date
JP2012505912A (ja) 2012-03-08
EP2342232A2 (en) 2011-07-13
WO2010048026A3 (en) 2010-07-15
BRPI0919832A8 (pt) 2019-01-08
CN102186884B (zh) 2014-08-13
EA021584B1 (ru) 2015-07-30
US8043618B2 (en) 2011-10-25
EA201170590A1 (ru) 2011-10-31
KR101370798B1 (ko) 2014-03-14
AU2009307841B2 (en) 2013-09-12
CA2741127C (en) 2015-06-02
JP5577345B2 (ja) 2014-08-20
US20120219563A1 (en) 2012-08-30
US8404240B2 (en) 2013-03-26
US20100098696A1 (en) 2010-04-22
AU2009307841A1 (en) 2010-04-29
UA101681C2 (ru) 2013-04-25
TWI381848B (zh) 2013-01-11
BRPI0919832A2 (pt) 2015-12-15
US20120009200A1 (en) 2012-01-12
AR073770A1 (es) 2010-12-01
ZA201101938B (en) 2012-08-29
WO2010048026A2 (en) 2010-04-29
NZ592369A (en) 2013-02-22
US8182815B2 (en) 2012-05-22
CA2741127A1 (en) 2010-04-29
TW201026325A (en) 2010-07-16
IL211807A0 (en) 2011-06-30
MX2011004317A (es) 2011-06-24
KR20110056554A (ko) 2011-05-30
CN102186884A (zh) 2011-09-14

Similar Documents

Publication Publication Date Title
CN103524620A (zh) 成纤维细胞生长因子受体-3(fgfr-3)抑制物和治疗的方法
JP6960485B2 (ja) 線維芽増殖因子受容体２に対するモノクローナル抗体
CN114040926A (zh) 结合cd123的多肽及其用途
KR20130060223A (ko) 상피세포 성장인자 수용체(ｅｇｆｒ)에 대한 항체 및 이의 용도
NZ724649A (en) Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
CN114127115A (zh) 结合CLEC12a的多肽及其用途
CN114040927A (zh) 结合cd33的多肽及其用途
JP2022529232A (ja) 抗ｈｅｒ２結合分子
WO2020228604A1 (zh) 抗trop-2抗体、其抗原结合片段及其医药用途
KR20220157686A (ko) 항-bcam 항체 또는 그의 항원 결합 단편
CN112272564B (zh) 可标靶vegfr2与vegfr3的双功能抗体
CN109476757A (zh) 抗-axl受体酪氨酸激酶抗体及其用途
CA3231586A1 (en) D3-binding molecules and uses thereof
WO2025026333A1 (en) Antibody against fgfr2b, method for preparing the same, and use thereof
TWI889920B (zh) 抗ｔｒｏｐ-２抗體、其抗原結合片段或其突變體、及其醫藥用途
TW202547875A (zh) 靶向成纖維細胞生長因子受體2IIIb的抗體及其應用
CN118496364A (zh) uPARAP特异性结合蛋白及其制备方法和应用
HK40076989B (zh) 抗cd22抗体及其用途
Kamat Combined use of multiple monoclonal antibodies targeting epidermal growth factor receptor for improved cancer therapeutics

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20140122